BOULDER, Colo.–(BUSINESS WIRE)–VitriVax, Inc., an innovative vaccine development and formulation technology company, today announced the close of an oversubscribed $87 million Series C financing. The investment was co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures with participation from Eli Lilly and Company as well as other existing investors. The funding will be used to advance VitriVax’s lead program, a Lyme disease vaccine candidate with a novel mechanism of action, into